Testing a new antibody with chemo for locally advanced throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent in writing and join voluntarily
- You are age 18 to 70, and your cancer is nasopharyngeal squamous cell cancer confirmed by biopsy
- Your cancer stage is locally advanced (not already spread to distant organs) and the tumor/lymph nodes can be measured
- Your tumor test shows EGFR is positive, and a specified score (Kaplan score) is above 70
- Your blood, liver, and kidney tests are strong enough for study treatment
- You have not had prior treatment with surgery (beyond biopsy) or radiation, and you haven’t had chemo, immunotherapy, or EGFR-targeted therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests whether adding a drug called TNF (a protein that may help the immune system fight cancer) to the usual chemoradiotherapy (chemotherapy plus radiation) improves outcomes for people with locally advanced nasopharyngeal cancer. If you join, you may receive the standard treatment with or without TNF, and the study will monitor how well the cancer responds and any side effects.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.